Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Tax Provisions (2016 - 2025)

Zevra Therapeutics' Tax Provisions history spans 11 years, with the latest figure at $501000.0 for Q4 2025.

  • For Q4 2025, Tax Provisions fell 96.74% year-over-year to $501000.0; the TTM value through Dec 2025 reached $3.4 million, down 77.56%, while the annual FY2025 figure was $3.4 million, 77.56% down from the prior year.
  • Tax Provisions reached $501000.0 in Q4 2025 per ZVRA's latest filing, up from -$433000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $15.4 million in Q4 2024 to a low of -$715000.0 in Q2 2022.
  • Average Tax Provisions over 5 years is $1.2 million, with a median of -$4000.0 recorded in 2022.
  • Peak YoY movement for Tax Provisions: plummeted 2475.0% in 2023, then skyrocketed 3041.43% in 2025.
  • A 5-year view of Tax Provisions shows it stood at $34000.0 in 2021, then tumbled by 200.0% to -$34000.0 in 2022, then skyrocketed by 620.59% to $177000.0 in 2023, then skyrocketed by 8584.18% to $15.4 million in 2024, then crashed by 96.74% to $501000.0 in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Tax Provisions are $501000.0 (Q4 2025), -$433000.0 (Q3 2025), and $2.2 million (Q2 2025).